AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

Nucala (300mg as three separate 100mg subcutaneous injections of mepolizumab) is licensed for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Nucala is the first-in-class anti-IL-5 biologic therapy. Nucala was specifically developed to treat appropriate severe asthma patients whose condition is driven by inflammation caused by eosinophils.

Nucala is currently used as an add-on maintenance therapy for severe eosinophilic asthma and for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), and is being investigated in ...

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as a treatment for patients with chronic ...

Nucala has been developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation. It is currently approved for use in Europe across four IL-5 mediated ...

Nucala is an add-on, prescription maintenance treatment for patients 6 years and older with severe eosinophilic asthma. [Read more: Walgreens' Find Care platform to support diabetes, asthma patients] ...

Nucala (3x 100mg subcutaneous injection of mepolizumab) is licensed for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

NUCALA reduces the number of eosinophils in the blood and in adults (18 years and above), can reduce the size of your polyps, relieve your nasal congestion and helps prevent surgery for nasal polyps.

Nucala is available as 100mg preservative-free, lyophilized powder for reconstitution in single-dose vials. For more information call (888) 825-5249 or visit Nucala.com.

GlaxoSmithKline PLC’s GSK -0.43% Nucala therapy has been approved to treat patients with severe asthma attacks in combination with other drugs, the Food and Drug Administration said Wednesday.